Carrie Brownstein brings 2 decades of experience in the field of oncology and other therapeutic areas addressing high unmet medical needs across biotech, and large and small pharma. Carrie served as the Chief Medical Officer (CMO) of Zentalis Pharmaceuticals, where she led a team responsible for the global development of a portfolio of small molecules targeting fundamental pathways in cancers, and as CMO of Cellectis Inc. a clinical stage biotech company, where she was responsible for advancing a portfolio of novel, first in class allogeneic CAR-T cell therapies for patients with hematologic malignancies. Previously, she held several senior leadership positions including Vice President of Global Clinical Research and Development (R&D), Therapeutic Area Head for Myeloid Diseases at Celgene, where she was responsible for the global clinical development and subsequent global regulatory approvals and launches of groundbreaking first in class products including REBLOZYL® for MDS and beta-thalassemia, INREBIC® for myelofibrosis, and IDHIFA® and ONUREG® for AML. Prior to Celgene, Carrie held positions of increasing responsibility at Regeneron Pharmaceuticals and Hoffman-La Roche. Carrie is a graduate of Memorial Sloan Kettering Cancer Center’s pediatric hematology-oncology fellowship program and completed her internship and residency training at Columbia Presbyterian Medical Center in New York. Dr. Brownstein practiced pediatric hematology and oncology at New York Presbyterian Columbia University and Mount Sinai Medical Center prior to joining industry. Dr. Brownstein received her M.D. from Tufts University School of Medicine and received her A.B. in Psychology from the University of Michigan.
